RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts

Human Gene Therapy

Volumn 17, Issue 7, 2006, Pages 751-766

  Grzelinski, Marius ^a   Urban Klein, Beata ^a   Martens, Tobias ^b   Lamszus, Katrin ^b   Bakowsky, Udo ^a   Höbel, Sabrina ^a   Czubayko, Frank ^a   Aigner, Achim ^a,c  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ALPHA INTERFERON; MESSENGER RNA; PLEIOTROPHIN; POLYETHYLENEIMINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; COLONY FORMATION; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; MOUSE; NONHUMAN; NUDE MOUSE; RNA DEGRADATION; RNA INTERFERENCE; TISSUE DISTRIBUTION;

ANIMALS; BRAIN NEOPLASMS; CARRIER PROTEINS; CYTOKINES; GENE THERAPY; GLIOBLASTOMA; MICE; MICE, INBRED STRAINS; MICROSCOPY, ATOMIC FORCE; NEOPLASM TRANSPLANTATION; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 33746267422     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.751     Document Type: Article

References (56)

1. ABUHARBEID, S., APEL, J., SANDER, M., FIEDLER, B., LANGER, M., ZUZARTE, M.L., CZUBAYKO, F., and AIGNER, A. (2004). Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem. Biophys. Res. Commun. 321, 403-412.
2. AIGNER, A. (2006). Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. J. Biotechnol. 124, 12-25.
3. AIGNER, A., FISCHER, D., MERDAN, T., BRUS, C., KISSEL, T., and CZUBAYKO, F. (2002a). Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 9, 1700-1707.
4. AIGNER, A., RAY, P.E., CZUBAYKO, F., and WELLSTEIN, A. (2002b). Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem. Cell Biol. 117, 1-11.
5. AIGNER, A., BRACHMANN, P., BEYER, J., JAGER, R., RAULAIS, D., VIGNY, M., NEUBAUER, A., HEIDENREICH, A., WEINKNECHT, S., CZUBAYKO, F., and ZUGMAIER, G. (2003). Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann. Oncol. 14, 1525-1529.
6. ANABOUSI, S., LAUE, M., LEHR, C.M., BAKOWSKY, U., and EHRHARDT, C. (2005). Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur. J. Pharm. Biopharm. 60, 295-303.
7. BEHR, J.P. (1997). The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 51, 34-36.
8. BOUSSIF, O., LEZOUALC'H, F., ZANTA, M.A., MERGNY, M.D., SCHERMAN, D., DEMENEIX, B., and BEHR, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92, 7297-7301.
9. BOWDEN, E.T., STOICA, G.E., and WELLSTEIN, A. (2002). Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J. Biol. Chem. 277, 35862-35868.
10. BROCKMANN, M.A., PAPADIMITRIOU, A., BRANDT, M., FILLBRANDT, R., WESTPHAL, M., and LAMSZUS, K. (2003a). Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res. 9, 4578-4585.
11. BROCKMANN, M.A., WESTPHAL, M., and LAMSZUS, K. (2003b). Improved method for the intracerebral engraftment of tumour cells and intratumoural treatment using a guide screw system in mice. Acta Neurochir. (Wien) 145, 777-781; discussion 781.
12. CHOUDHURI, R., ZHANG, H.T., DONNINI, S., ZICHE, M., and BICKNELL, R. (1997). An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 57, 1814-1819.
13. COURTY, J., DAUCHEL, M.C., CARUELLE, D., PERDERISET, M., and BARRITAULT, D. (1991). Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem. Biophys. Res. Commun. 180, 145-151.
14. CZUBAYKO, F., SCHULTE, A.M., MISSNER, S.C., HSIEH, S.S., COLLEY, K.J., and WELLSTEIN, A. (1995). Molecular and pharmacologic targeting of angiogenesis factors: The example of pleiotrophin. Breast Cancer Res. Treat. 36, 157-168.
15. CZUBAYKO, F., SCHULTE, A.M., BERCHEM, G.J., and WELLSTEIN, A. (1996). Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. U.S.A. 93, 14753-14758.
16. DAVIS, F.G., KUPELIAN, V., FREELS, S., MCCARTHY, B., and SURAWICZ, T. (2001). Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. J. Neurooncol. 3, 152-158.
17. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
18. FANG, W.J., HARTMANN, N., CHOW, D., RIEGEL, A.T., and WELLSTEIN, A. (1992). Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J. Biol. Chem. 267, 25889-25897.
19. FISCHER, D., OSBURG, B., PETERSEN, H., KISSEL, T., and BICKEL, U. (2004). Effect of polyethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metab. Dispos. 32, 983-992.
20. GONDI, C.S., LAKKA, S.S., DINH, D.H., OLIVERO, W.C., GUJRATI, M., and RAO, J.S. (2004). RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23, 8486-8496.
21. GOULA, D., REMY, J.S., ERBACHER, P., WASOWICZ, M., LEVI, G., ABDALLAH, B., and DEMENEIX, B.A. (1998). Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther. 5, 712-717.
22. GRZELINSKI, M., BADER, N., CZUBAYKO, F., and AIGNER, A. (2005). Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117, 942-951.
23. HANNON, G.J., and ROSSI, J.J. (2004). Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378.
24. HOLLAND, E.C. (2000). Glioblastoma multiforme: The terminator. Proc. Natl. Acad. Sci. U.S.A. 97, 6242-6244.
25. HORNUNG, V., GUENTHNER-BILLER, M., BOURQUIN, C., ABLASSER, A., SCHLEE, M., UEMATSU, S., NORONHA, A., MANOHARAN, M., AKIRA, S., DE FOUGEROLLES, A., ENDRES, S., and HARTMANN, G. (2005). Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270.
26. HOWARD, K. (2003). Unlocking the money-making potential of RNAi. Nat. Biotechnol. 21, 1441-1446.
27. JENSEN, R.L. (1998). Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg. Neurol. 49, 189-195; discussion 196.
28. JUDGE, A.D., SOOD, V., SHAW, J.R., FANG, D., MCCLINTOCK, K., and MACLACHLAN, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
29. KICHLER, A. (2004). Gene transfer with modified polyethylenimines. J. Gene Med. 6(Suppl. 1), S3-S10.
30. KURTZ, A., SCHULTE, A.M., and WELLSTEIN, A. (1995). Pleiotrophin and midkine in normal development and tumor biology. Crit. Rev. Oncog. 6, 151-177.
31. LAAROUBI, K., DELBE, J., VACHEROT, F., DESGRANGES, P., TARDIEU, M., JAYE, M., BARRITAULT, D., and COURTY, J. (1994). Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 10, 89-98.
32. LI, Y.S., MILNER, P.G., CHAUHAN, A.K., WATSON, M.A., HOFFMAN, R.M., KODNER, C.M., MILBRANDT, J., and DEUEL, T.F. (1990). Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 250, 1690-1694.
33. LU, K.V., JONG, K.A., KIM, G.Y., SINGH, J., DIA, E.Q., YOSHIMOTO, K., WANG, M.Y., CLOUGHESY, T.F., NELSON, S.F., and MISCHEL, P.S. (2005). Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280, 26953-26964.
34. MALERCZYK, C., SCHULTE, A.M., CZUBAYKO, F., BELLON, L., MACEJAK, D., RIEGEL, A.T., and WELLSTEIN, A. (2005). Ribozyme targeting of the growth factor pleiotrophin in established tumors: A gene therapy approach. Gene Ther. 12, 339-346.
35. MENTLEIN, R., and HELD-FEINDT, J. (2002). Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem. 83, 747-753.
36. MILNER, P.G., LI, Y.S., HOFFMAN, R.M., KODNER, C.M., SIEGEL, N.R., and DEUEL, T.F. (1989). A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: Purification and N-terminal amino acid sequence. Biochem. Biophys. Res. Commun. 165, 1096-1103.
37. MOOG-LUTZ, C., DEGOUTIN, J., GOUZI, J.Y., FROBERT, Y., BRUNET-DE CARVALHO, N., BUREAU, J., CREMINON, C., and VIGNY, M. (2005), Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039-26048.
38. MULLER, S., KUNKEL, P., LAMSZUS, K., ULBRICHT, U., LORENTE, G.A., NELSON, A.M., VON SCHACK, D., CHIN, D.J., LOHR, S.C., WESTPHAL, M., and MELCHER, T. (2003). A role for receptor tyrosine phosphatase ζ in glioma cell migration. Oncogene 22, 6661-6668.
39. MURAMATSU, T. (2002). Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. (Tokyo) 132, 359-371.
40. OBERLE, V., BAKOWSKY, U., ZUHORN, I.S., and HOEKSTRA, D. (2000). Lipoplex formation under equilibrium conditions reveals a three-step mechanism. Biophys. J. 79, 1447-1454.
41. OSBURG, B., PEISER, C., DOMLING, D., SCHOMBURG, L., KO, Y.T., VOIGT, K., and BICKEL, U. (2002). Effect of endotoxin on expression of TNF receptors and transport of TNF-α at the blood-brain barrier of the rat. Am. J. Physiol. Endocrinol. Metab. 283, E899-E908.
42. POWERS, C., AIGNER, A., STOICA, G.E., MCDONNELL, K., and WELLSTEIN, A. (2002). Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277, 14153-14158.
43. RAUVALA, H. (1989). An 18-kD heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. 8, 2933-2941.
44. SATYAMOORTHY, K., OKA, M., and HERLYN, M. (2000). An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res. 13(Suppl. 8), 87-93.
45. SCHIFFELERS, R.M., ANSARI, A., XU, J., ZHOU, Q., TANG, Q., STORM, G., MOLEMA, G., LU, P.Y., SCARIA, P.V., and WOODLE, M.C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
46. SHANKAR, P., MANJUNATH, N., and LIEBERMAN, J. (2005). The prospect of silencing disease using RNA interference. JAMA 293, 1367-1373.
47. SIOUD, M. (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090.
48. SIOUD, M. (2006a). RNA interference below the immune radar. Nat. Biotechnol. 24, 521-522.
49. SIOUD, M. (2006b). Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: A central role for 2′-hydroxyl uridines in immune responses. Eur. J. Immunol. 36, 1222-1230.
50. ULBRICHT, U., BROCKMANN, M.A., AIGNER, A., ECKERICH, C., MULLER, S., FILLBRANDT, R., WESTPHAL, M., and LAMSZUS, K. (2003). Expression and function of the receptor protein tyrosine phosphatase ζ and its ligand pleiotrophin in human astrocytomas. J. Neuropathol. Exp. Neurol. 62, 1265-1275.
51. UPRICHARD, S.L. (2005). The therapeutic potential of RNA interference. FEBS Lett. 579, 5996-6007.
52. URBAN-KLEIN, B., WERTH, S., ABUHARBEID, S., CZUBAYKO, F., and AIGNER, A. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466.
53. WAGNER, E., KIRCHEIS, R., and WALKER, G.F. (2004). Targeted nucleic acid delivery into tumors: New avenues for cancer therapy. Biomed. Pharmacother. 58, 152-161.
54. WELLSTEIN, A., LUPU, R., ZUGMAIER, G., FLAMM, S.L., CHEVILLE, A.L., DELLI BOVI, P., BASILICO, C., LIPPMAN, M.E., and KERN, F.G. (1990). Autocrine growth stimulation by secreted Kaposi's fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ. 1, 63-71.
55. WELLSTEIN, A., FANG, W.J., KHATRI, A., LU, Y., SWAIN, S.S., DICKSON, R.B., SASSE, J., RIEGEL, A.T., and LIPPMAN, M.E. (1992). A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J. Biol. Chem. 267, 2582-2587.
56. ZHANG, N., and DEUEL, T.F. (1999). Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr. Opin. Hematol. 6, 44-50.